SCHEMBL18074682

SCHEMBL18074682

O=c1[nH]sc2ccc(Br)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.53
DDAH1 O94760 1/20 0.53
CASP3 P42574 1/20 0.53
HTT P42858 1/20 0.53
CACNA1B Q00975 1/20 0.53
APBA1 Q02410 1/20 0.53
POLB P06746 1/20 0.47
MAOA P21397 1/20 0.46
PIM1 P11309 3/20 0.46
CHEK1 O14757 2/20 0.46
FLT3 P36888 2/20 0.46
MAP2K1 Q02750 2/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
JAK2 O60674 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13455388 0.84 ALDH1A1 (0.61) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL5498592 0.76 ALDH1A1 (0.72) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL79949 0.76 LMNA (0.53) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL4722581 0.76 MAPT (0.53) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL3868022 0.76 MAPT (0.53) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL26645428 0.76 MAPT (0.53) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL29881669 0.76 ALDH1A1 (0.72) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL6238353 0.73 PIM1 (0.44) LMNAMAPTPIM1CHEK1FLT3
SCHEMBL8807782 0.72 KDM4E (0.48) LMNAALDH1A1MAPTKDM4EDDAH1
SCHEMBL17272797 0.72 ALDH1A1 (0.48) LMNAALDH1A1MAPTKDM4EDDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265601-A2 USE OF BENZISOSELAZOLE DERIVATIVE FOR ANTI-CORONAVIRUS AND CONTROL OF INTERSTITIAL LUNG DISEASE (ILD) RELATED TO CORONAVIRUS Shanghai Yuanxi Medicine Corp. (CN) 2023-10-25 EP disclosed
US-20230210819-A1 USE OF BENZISOSELAZOLE DERIVATIVE FOR ANTI-CORONAVIRUS AND CONTROL OF INTERSTITIAL LUNG DISEASE (ILD) RELATED TO CORONAVIRUS SHANGHAI YUANXI MEDICINE CORP. (CN) 2023-07-06 US disclosed
EP-3271354-A1 NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE Pfizer Inc (US) 2018-01-24 EP disclosed
WO-2016147144-A1 NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE PFIZER INC. (US) 2016-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210819-A1 USE OF BENZISOSELAZOLE DERIVATIVE FOR ANTI-CORONAVIRUS AND CONTROL OF INTERSTITIAL LUNG DISEASE (ILD) RELATED TO CORONAVIRUS ACE, SARS1, ACE2 LMNA 981/4885ALDH1A1 1235/4885MAPT 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.